摘要
硼替佐米作为一细胞毒药物,临床主要不良反应包括虚弱、胃肠道反应、周围神经病变、发热和血液学毒性等,但针对低钠血症这一临床常见抗肿瘤治疗并发症的研究和报道较少。本文通过文献检索和综述,对一例硼替佐米治疗多发性骨髓瘤致严重低钠血症病例进行了分析和探讨,发现临床硼替佐米的使用与顽固性低钠血症的发生存在相关性,病因可能为硼替佐米导致了抗利尿激素(antidiuretic hormone,ADH)的不适当分泌,应以限水补钠为首选有效治疗措施。此研究结果提示今后对于采用硼替佐米治疗的患者应严格定期监测血清钠水平,如患者出现意识障碍,必须考虑是否有发生低钠血症的可能性。
Bortezomib is a cytotoxic agent with various adverse effects such as fatigue, gastrointestinal adverse reactions, peripheral neuropathy,pyrexia, hematological toxicities and so on. We report a case of severe hyponatremia in a 73-year-old male patient with multiple myeloma treatedwith bortezomib. Through literature retrieval, we believe that hyponatremia may be a treatment-related adverse event after bortezomib administration.A syndrome of inappropriate secretion of antidiurectic hormone （SIADH） is diagnosed, and bortezomib is identified as its cause. Oral sodiumsupplementation and fluid restriction are the preferred effective treatment. In conclusion, serum sodium levels must be monitored strictly in patientstreated by bortezomib, and hyponatremia should be considered in bortezomib-treated patients with cognitive dysfunction.
出处
《药品评价》
CAS
2016年第10期62-64,共3页
Drug Evaluation
